T16A(inh)-C01(Cat No.:I012189)is a potent and selective inhibitor of the TGF-β (transforming growth factor-beta) receptor, designed to block the activation of this signaling pathway. TGF-β plays a crucial role in fibrosis, immune regulation, and cancer progression, making it a critical target for therapeutic intervention. By inhibiting TGF-β receptor activity, T16A(inh)-C01 aims to reduce excessive fibrosis and inflammation, offering potential for treating fibrotic diseases, autoimmune conditions, and certain cancers. This compound is being investigated for its ability to selectively modulate TGF-β signaling without broadly affecting immune system function.